Celcuity Inc. (CELC)

Insider Trading Filed: 2026-05-06

Director David Dalvey sold 25,000 shares at $140.68 per share on May 4, 2026, representing a significant insider sale of approximately $3.52 million through a pre-planned Rule 10b5-1 trading arrangement established in August 2025.
The sale was executed through Brightstone Venture Capital Fund, LP under a pre-established trading plan, indicating this was a scheduled, non-discretionary transaction rather than a response to current events, reducing concerns about sudden loss of confidence.
Dalvey retains 65,000 shares of indirect beneficial ownership through Brightstone, demonstrating continued meaningful investment in the company despite the substantial share sale.

Insider Trading Filed: 2026-05-06

Director Richard E. Buller executed a significant net selling transaction on 05/04/2026, disposing of 8,800 shares across multiple tranches at prices ranging from $137 to $143.24 while acquiring only 9,000 shares at $5.10, resulting in a net reduction of beneficial ownership from the trust.
The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025, indicating pre-planned disposition rather than reactive selling and reducing concerns about sudden loss of confidence.
Buller's final beneficial ownership stands at 6,760 shares held indirectly through a trust (after the reported transactions), representing a substantial decrease in his stake in the company despite the option exercise.
The wide price range for share sales ($137-$143.24) suggests execution over time through the 10b5-1 plan, with the timing appearing strategically planned rather than emergency liquidation.

Current Report Filed: 2026-05-01

Celcuity announced positive Phase 3 VIKTORIA-1 trial results showing gedatolisib plus fulvestrant with or without palbociclib demonstrated statistically significant and clinically meaningful PFS improvement compared to alpelisib in PIK3CA mutant HR+/HER2- breast cancer patients, representing a key milestone for the lead candidate.
The company plans to submit a supplemental NDA (sNDA) to the FDA and present data at the 2026 ASCO Annual Meeting, indicating near-term regulatory action and clinical validation that could accelerate commercialization timelines and market adoption.
Both gedatolisib regimens demonstrated manageable safety profiles with no new safety signals, addressing a critical risk factor for regulatory approval and patient acceptance in the competitive PI3K inhibitor landscape.
The trial's secondary endpoint also met statistical significance for gedatolisib plus fulvestrant alone versus alpelisib plus fulvestrant, potentially expanding the addressable patient population and commercial opportunity beyond the primary analysis.

Insider Trading Filed: 2026-04-13

Richard J. Nigon, a director of Celcuity Inc., has disposed of 10,000 shares of the company's common stock, reducing his direct beneficial ownership to 79,035 shares.
The transaction was made on April 9, 2026, and the shares were disposed of at a price of $0 per share.
Insider transactions can provide insights into management's views on the company's prospects and valuation.

Insider Trading Filed: 2026-04-02

The reporting person Richard E. Buller, who is a director of Celcuity Inc. (CELC), has engaged in a series of transactions involving the company's common stock, including the exercise of stock options and subsequent sales.
The transactions were conducted pursuant to a Rule 10b5-1 trading plan, indicating a planned approach to managing his equity holdings in the company.
The reporting person continues to hold a significant indirect beneficial ownership in Celcuity Inc. through a trust, suggesting ongoing involvement and commitment to the company.

Annual Report Filed: 2026-03-26

Celcuity Inc. (CELC) has experienced significant growth in its common stock, additional paid-in capital, and retained earnings over the past few years, indicating potential business expansion and profitability.
The company has various financial instruments, including senior notes, convertible notes, options, and warrants, which could impact its capital structure and financial performance.
Celcuity's research and development expenses have been a significant portion of its overall expenses, suggesting a focus on innovation and product development.

Current Report Filed: 2026-03-25

Celcuity Inc. reported its Q4 and fiscal year 2025 financial results, indicating the company's performance and financial condition for the period.
The company's press release regarding the financial results has been furnished as an exhibit, providing investors with additional information.
Celcuity Inc. is a publicly-traded company, with its common stock listed on the Nasdaq Stock Market.

Insider Trading Filed: 2026-02-13

Charles R. Romp, a director of Celcuity Inc. (CELC), acquired 215 shares of the company's common stock on February 11, 2026, indicating his continued commitment to the firm.
The shares were acquired through a restricted stock grant that will vest upon the earlier of the 2026 annual meeting or April 30, 2026, aligning Romp's interests with those of shareholders.
Insider transactions can provide insights into management's confidence in the company's prospects, though the significance of this particular transaction may be limited given the small size of the acquisition.

Current Report Filed: 2026-02-12

Celcuity Inc. has appointed Charles (Chip) R. Romp as a new director, expanding the board from seven to eight members.
Mr. Romp qualifies as an independent director and will receive standard non-employee director compensation, including an annual cash retainer and equity award.
There are no known relationships or related transactions between Mr. Romp and the company that would raise concerns.

Insider Trading Filed: 2026-01-29

Insider David Dalvey sold 20,000 shares of Celcuity Inc. (CELC) at an average price of $120.0269, reducing his indirect beneficial ownership to 90,000 shares.
The sales were made pursuant to a Rule 10b5-1 trading plan, suggesting planned and structured insider selling rather than a sudden or reactive transaction.
Insider selling can sometimes signal management's lack of confidence in the company's future prospects, though the overall significance depends on the context and magnitude of the transactions.

Insider Trading Filed: 2026-01-09

The reported transaction indicates that director Richard Nigon sold 19,975 shares of Celcuity Inc. (CELC) common stock on December 15, 2025 at $0 per share.
Nigon's beneficial ownership in the company has decreased from 109,010 shares to 89,035 shares following this transaction.
Insider selling transactions can sometimes signal management's lack of confidence in the company's future prospects, though additional context would be needed to draw firm conclusions.

Important Information